



Trend of OPDIVO

Sales Trend of OPDIVO by Each Cancer




Number of Patients Newly Prescribed with OPDIVO by Each Cancer (Estimation)



Source: Estimation from external and internal data


Trend of total sales of ICPIs and OPDIVO share



Source: External data


Number of GC* Patients per year in Japan

* : Unresectable Advanced or Recurrent GC



Estimation based on internal survey (2020)

Prescription Ratio in Patients Newly Treated* for 1L GC




*Patients starting treatment within the last 3 month

Source: External data (Nov 2021~Feb 2024: n=200~204)


Number of ESC* Patients per year in Japan

* : Unresectable Advanced or Recurrent ESC



Estimation based on internal survey (2022)


Prescription Ratio in Patients Newly Treated* for 1L ESC(Squamous Cell Carcinoma)



*Patients starting treatment within the last 3 month


Source: External data (May 2022~Jan 2024: n=150~155)

Number of ESC(Perioperative)Patients per year in Japan



Estimation based on internal survey (2022)

Prescription Ratio in Patients Newly Treated* for ESC(adjuvant chemotherapy)




*Patients starting treatment within the last 3 months

Source: External data (Mar 2022~Mar 2024 n=130~152)


Number of NSCLC* Patients per year in Japan

* Unresectable Advanced or Recurrent NSCLC

1L



Prescription Ratio in Patients Newly Treated* for 1L NSCLC




(Before approval)

*Patients starting treatment within the last 1 month (Except Driver Mutation)


Source: External data (Nov 2020~Mar 2024: n=167~245)

Number of Bladder Cancer(Perioperative)Patients per year in Japan



Estimation based on internal survey (2022)

Prescription Ratio in Patients Newly Treated* for Bladder Cancer (adjuvant chemotherapy)




*Patients starting treatment within the last 3 months

Source: External data (Jan 2022~Nov 2023: n=200)

Number of RCC* Patients per year in Japan




* : Unresectable or Metastatic RCC



Estimation based on internal survey (2022)

Prescription Ratio in Patients Newly Treated* for 1L RCC



*Patients starting treatment within the last 3 months

Source: External data (Sep 2018~Dec 2023: n=46~150)